Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01686386 | Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 60 | Gruppo Italiano Studio LinfomiOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01278602 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | unknown | Phase 2 | 196 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01780766 | Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging | unknown | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment(RIAltO) | unknown | Phase 3 | 670 | University of LiverpoolOTHER | 1 | Oct 15, 2012 | clinicaltrials |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | unknown | Phase 3 | 360 | European Mantle Cell Lymphoma NetworkOTHER | 3 | Sep 10, 2012 | clinicaltrials |
| NCT01670812 | Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia | unknown | Phase 3 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 22, 2012 | clinicaltrials |
| NCT01665014 | Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma | unknown | Phase 2 | 50 | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, GliwiceOTHER | 1 | Aug 17, 2012 | clinicaltrials |
| NCT01657955 | Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia(CLL) | unknown | Phase 3 | 96 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2012 | clinicaltrials |
| NCT00772655 | Zevalin® First Line in Follicular Lymphoma | unknown | Phase 2 | 60 | Charite University, Berlin, GermanyOTHER | 0 | Aug 2, 2012 | clinicaltrials |
| NCT01572688 | Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma(MM) | unknown | N/A | 60 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 2, 2012 | clinicaltrials |
| NCT01134484 | VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) | unknown | Phase 3 | 480 | Michele CavoOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT01295593 | Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) | unknown | Phase 1 / Phase 2 | 33 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00998270 | Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | unknown | Phase 2 / Phase 3 | 185 | Tehran University of Medical SciencesOTHER | 1 | Jun 4, 2012 | clinicaltrials |
| NCT01010243 | Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial(MM03) | unknown | Phase 1 / Phase 2 | 54 | University of RegensburgOTHER | 1 | May 30, 2012 | clinicaltrials |
| NCT01314625 | A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients | unknown | — | 10 | University of ArkansasOTHER | 1 | May 16, 2012 | clinicaltrials |
| NCT01555359 | Telomerase Activity as a Marker For Mobilization Quality | unknown | — | 50 | Rabin Medical CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT01532856 | Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years | unknown | Phase 3 | 64 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01302912 | Lymphoma in the Orbit | unknown | — | 50 | University of ZurichOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma(REAL07) | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00530140 | Idiotypic Vaccination for Follicular Lymphoma Patients(FLIDVAX2006) | unknown | Phase 2 | 100 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 6, 2011 | clinicaltrials |
| NCT01042717 | Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection | unknown | N/A | 10 | Shi, Patricia, M.D.INDIV | 1 | Sep 27, 2011 | clinicaltrials |
| NCT01114048 | Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)(KMM-97) | unknown | Phase 2 | 78 | Chonnam National University HospitalOTHER | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia(Bortezomib) | unknown | Phase 2 | 20 | Clinical Service, ChinaINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT01051115 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease(D'ACCORD) | unknown | Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 31, 2011 | clinicaltrials |
| NCT01423344 | Clinical Evaluation of the Serum Free Light Chain Analysis | unknown | — | 30 | Charlotte Toftmann HansenOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma(DLCL04) | unknown | Phase 3 | 399 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | unknown | Phase 3 | 534 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT01249690 | Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | unknown | Phase 4 | 100 | Second Military Medical UniversityOTHER | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00935597 | Host Dendritic Cells in Allograft Patients | unknown | Phase 1 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 29, 2010 | clinicaltrials |
| NCT00923663 | Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Sep 28, 2010 | clinicaltrials |
| NCT00892827 | Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia | unknown | Phase 2 | 10 | Wolfson Medical CenterOTHER_GOV | 1 | Sep 14, 2010 | clinicaltrials |
| NCT00628238 | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 2 | 80 | Chronic Lymphocytic Leukemia Research ConsortiumNETWORK | 1 | Sep 10, 2010 | clinicaltrials |
| NCT01171443 | The Pathophysiology of Bortezomib Induced Peripheral Neuropathy(BIPN) | unknown | — | 30 | Wolfson Medical CenterOTHER_GOV | 1 | Jul 28, 2010 | clinicaltrials |
| NCT01151358 | Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy(MERIT-NHL) | unknown | — | 150 | University Hospital, SaarlandOTHER | 1 | Jun 28, 2010 | clinicaltrials |
| NCT00508209 | Bortezomib and High-dose Melphalan at Myeloma Relapse | unknown | Phase 2 | 50 | Nordic Myeloma Study GroupOTHER | 3 | Jun 22, 2010 | clinicaltrials |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 / Phase 2 | 15 | Kaplan Medical CenterOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT01066429 | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Hospital Universitario Principe de AsturiasOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00571168 | Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy(EmNa) | unknown | Phase 3 | 362 | Heidelberg UniversityOTHER | 1 | Jan 12, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Apr 5, 2013source: clinicaltrials